Harmony Biosciences partners with Beacon Biosignals for EEG in hypersomnia

Harmony Biosciences (HRMY) announced a collaboration with Beacon Biosignals, which deals in AI-driven neurophysiology and precision drug development, to incorporate quantitative electroencephalography, or EEG, measurements into two of Harmony’s Phase 3 studies of HBS-301 for Narcolepsy and Idiopathic Hypersomnia. The collaboration will support Harmony’s primary objective of assessing excessive daytime sleepiness by complementing traditional patient-reported outcomes, such as the Epworth Sleepiness Scale, with objective sleep EEG data. Through this study, Beacon’s FDA 510(k)-cleared Waveband EEG headband and AI-driven algorithms will be used to capture at-home brain data across consecutive nights of sleep. Additionally, it will assess daytime sleepiness with continuous EEG data enabled by the Waveband’s wireless, low-profile design. The addition of quantitative EEG-based endpoints aims to allow for more robust characterization of both daytime and nighttime sleep patterns.